Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

Speaking to the MEN Nirjeet said ... This month, he has set up a support group with fellow model and The Vitiligo Society ambassador, Rueben Sam, that is to regularly meet in Manchester.

Patients with vitiligo who received long-term NBUVB phototherapy vs no phototherapy were associated with reduced risks for cardiometabolic diseases.